Belite Bio (NASDAQ:BLTE) Price Target Raised to $314.00

Belite Bio (NASDAQ:BLTE – Free Report) had its target price lifted by Canaccord Genuity Group from $303.00 to $314.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also weighed in on BLTE. Morgan Stanley boosted their price target on Belite Bio from $201.00 to $206.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Benchmark reiterated a “buy” rating on shares of Belite Bio in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a report on Friday, October 2nd. Jefferies Financial Group reissued a “hold” rating on shares of Belite Bio in a report on Wednesday, September 9th. Finally, Cantor Fitzgerald raised their target price on shares of Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $226.91.

View Our Latest Report on BLTE

Belite Bio Price Performance

Shares of NASDAQ BLTE opened at $156.23 on Monday. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of -57.23 and a beta of -1.19. The business has a 50-day moving average of $159.02 and a 200-day moving average of $160.10. Belite Bio has a fifty-two week low of $105.88 and a fifty-two week high of $200.00.

Belite Bio (NASDAQ:BLTE – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.19. On average, sell-side analysts expect that Belite Bio will post -3.06 EPS for the current year.

Insider Activity

In related news, CFO Hao-Yuan Chuang sold 17,962 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $196.42, for a total value of $3,528,096.04. Following the completion of the sale, the chief financial officer directly owned 26,038 shares in the company, valued at approximately $5,114,383.96. This trade represents a 40.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Yu-Hsin Lin sold 26,000 shares of Belite Bio stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $196.56, for a total value of $5,110,560.00. Following the transaction, the chief executive officer owned 70,134 shares of the company’s stock, valued at $13,785,539.04. The trade was a 27.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 170,330 shares of company stock valued at $32,301,098. 13.29% of the stock is owned by company insiders.

Institutional Trading of Belite Bio

Several institutional investors and hedge funds have recently bought and sold shares of BLTE. Aquatic Capital Management LLC acquired a new stake in shares of Belite Bio in the third quarter valued at approximately $921,000. Great Point Partners LLC bought a new position in shares of Belite Bio during the 3rd quarter worth approximately $12,736,000. Marshall Wace LLP acquired a new position in shares of Belite Bio during the 3rd quarter worth approximately $15,282,000. State Street Corp increased its holdings in shares of Belite Bio by 6.9% during the 3rd quarter. State Street Corp now owns 34,044 shares of the company’s stock worth $5,781,000 after acquiring an additional 2,196 shares during the last quarter. Finally, Alberta Investment Management Corp acquired a new position in shares of Belite Bio during the 3rd quarter worth approximately $4,076,000. Institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Recommended Stories

Analyst Recommendations for Belite Bio (NASDAQ:BLTE)

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.